CEL-SCI Stock Gaps Down On Today's Open (CVM)
NEW YORK (TheStreet) -- Shares of CEL-SCI Corporation (AMEX:CVM) were gapping down Thursday morning with an open price 14.3% lower than Wednesday's closing price. The stock closed at 42 cents Wednesday and opened today's trading at 36 cents. The average volume for CEL-SCI has been 1.6 million shares per day over the past 30 days. CEL-SCI has a market cap of $109.6 million and is part of the health care sector and drugs industry. Shares are up 47.3% year to date as of the close of trading on Wednesday. CEL-SCI Corporation researches and develops drugs and vaccines. The company's lead product, Multikine, is under the Phase III clinical trial for the treatment of head and neck cancer. TheStreet Ratings rates CEL-SCI as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full CEL-SCI Ratings Report. Get more investment ideas from our investment research center.
Latest Headlines about CVM
-
Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail!
08:15AM 04/26/13
-
BioCryst Won't Profit From Bird Flu Outbreak in China
03:11PM 04/08/13
-
Biotech Stock Mailbag: Ampio, Cel-Sci and Ziopharm
05:30AM 04/05/12
-
Biotech Stock Mailbag: Xoma
08:53AM 09/02/11
-
Biotech Data Mining Comes Up Empty
07:19AM 06/29/11
-
Cel-Sci Settles Over South African Partner Flap
09:29AM 05/17/11
-
Cel-Sci: The Multikine Sweet 16
12:09PM 05/03/11
Latest from TheStreet Wire
-
Avago Technologies Ltd (AVGO): Today's Featured Electronics Laggard
05:01PM 05/23/13
-
Wynn Resorts Ltd (WYNN): Today's Featured Services Laggard
05:01PM 05/23/13
-
Pentair Ltd (PNR): Today's Featured Industrial Laggard
05:01PM 05/23/13
-
Microsoft Corporation (MSFT): Today's Featured Computer Software & Services Laggard
05:01PM 05/23/13
-
Michael Kors Holdings Ltd (KORS): Today's Featured Retail Laggard
05:01PM 05/23/13
-
Devon Energy Corp (DVN): Today's Featured Basic Materials Laggard
05:01PM 05/23/13
-
Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard
05:01PM 05/23/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
